Meropenem microbiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 1: Line 1:
__NOTOC__
{{Meropenem}}
{{CMG}}
==Microbiology==
==Microbiology==


Line 7: Line 14:
Meropenem should not be used to treat methicillin-resistant [[staphylococci]] (MRSA).   
Meropenem should not be used to treat methicillin-resistant [[staphylococci]] (MRSA).   
In vitro tests show meropenem to act synergistically with aminoglycoside antibiotics against some  
In vitro tests show meropenem to act synergistically with aminoglycoside antibiotics against some  
isolates of [[Pseudomonas aeruginosa]].
isolates of [[Pseudomonas aeruginosa]].<ref>{{Cite web | last = | first = |title = http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050706s022lbl.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050706s022lbl.pdf | publisher = |date = | accessdate = }}</ref>
 
==References==
{{Reflist}}
 
{{FDA}}
 
[[Category:Antibiotics]]
[[Category:Wikinfect]]

Revision as of 21:50, 20 December 2013


Meropenem
MERREM® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings
Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
Compatibility, Reconstitution, and Stability
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Microbiology

Meropenem is a broad-spectrum Carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and [[Pseudomonas aeruginosa]]; and PBPs 1, 2 and 4 of Staphylococcus aureus. Bactericidal concentrations (defined as a 3 log10 reduction in cell counts within 12 to 24 hours) are typically 1-2 times the bacteriostatic concentrations of meropenem, with the exception of Listeria monocytogenes against which lethal activity is not observed. Meropenem has significant stability to hydrolysis by β-lactamases of most categories, both penicillinases and cephalosporinases produced by Gram-positive and Gram-negative bacteria. Meropenem should not be used to treat methicillin-resistant staphylococci (MRSA). In vitro tests show meropenem to act synergistically with aminoglycoside antibiotics against some isolates of Pseudomonas aeruginosa.[1]

References

  1. "http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050706s022lbl.pdf" (PDF). External link in |title= (help)

Adapted from the FDA Package Insert.